This article was originally published in The Tan Sheet
Steven Bowman tapped interim CEO, filling in until a replacement is found for Richard Piazza, the company announces May 11. Piazza stepped down from the president, CEO and chairman of the board positions he assumed last November from Elliot Friedman, who remains a board member (1"The Tan Sheet" Oct. 18, 1999, p. 20). Former PharmaPrint corporate counsel and board member Phil Trad temporarily assumed the responsibilities of president, treasurer and company secretary; the board remains without a chairman. Although a search is underway, PharmaPrint says restructuring debt and shoring up the firm's finances are more pressing priorities than recruiting a president or permanent replacements for the other positions (2"The Tan Sheet" Feb. 28, p. 8)
You may also be interested in...
PharmaPrint is counting on several strategic initiatives, including negotiating payment plans with vendors and selling shares of its privately held Internet company, to counteract losses stemming from a terminated agreement with American Home Products.
Six vitamin/herbal combination products to be distributed by online superstore Value America under a recent agreement between the firms. PharmaPrint and Charlottesville, Va.-based Value America will co-promote the new line, marketed under the PharmaPrint label, through major media outlets. Value America is PharmaPrint's second e-commerce partner; the Irvine, Calif.-based supplement manufacturer previously announced a distribution agreement with healthzone.com (1"The Tan Sheet" Sept. 6, p. 11). PharmaPrint also names Richard Piazza as new president and CEO. Piazza is the former CEO of VitaGen, a biotech company specializing in combating liver disease. He replaces Elliot Friedman, who remains as full-time chairman
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC